Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
· CA4P and checkpoint inhibitor combination nearly doubles amount of tumor necrosis SOUTH SAN FRANCISCO, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a...
-
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
-
Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapyPreliminary data suggest immuno-oncology...
-
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
-
New Data Continue to Show OXi4503 has Significant Potential as New Treatment for AMLOXi4503 Recently Prioritized as Lead Drug Development Program at Mateon SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017...
-
Company to terminate FOCUS study due to lack of clear efficacy signal in the third interim analysisCompany to reduce headcount, concentrate on OXi4503 for acute myeloid leukemia (AML) SOUTH SAN...
-
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan...
-
Primary Endpoint - Early Progression Free Survival data favors CA4PCA4P continues to be safe and well-toleratedNext interim analysis expected in September SOUTH SAN FRANCISCO, Calif., Aug. 16, 2017 ...
-
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
Recruitment rate significantly increased following initial positive interim analysisInterim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH...